New prognostic factors in melanoma: mRNA tumour markers

European Journal of Cancer

Volumn 34, Issue SUPPL. 3, 1998, Pages 37-41

  Keilholz, U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Melanoma; mRNA; Prognostic factor; RT PCR; Tumour markers

Indexed keywords

MESSENGER RNA; MONOPHENOL MONOOXYGENASE; TUMOR MARKER;

CONFERENCE PAPER; HUMAN; MELANOMA; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031661690     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(97)10163-0     Document Type: Conference Paper

References (37)

1. Liotta L, Stetler-Stevenson G. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991, 51, 5054-5059.
2. Goldblatt SA, Nadel FM. Cancer cells in the circulating blood: a critical review II. Acta Cytol 1965, 9, 6-20.
3. Lindenmann F, Schlimok G, Dirschedl P, Witte J, Riethmüller G. Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients. Lancet 1992, 340, 685-689.
4. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991, 9, 1749-1756.
5. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy - results of a 3 year median follow-up. Br J Cancer 1994, 69, 566-571.
6. Manni JL, Easton D, Berger U, et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years follow-up. Eur J Cancer 1991, 27, 1552-1555.
7. Moss TJ, Sanders DG. Detection of neuroblastoma cells in blood. J Clin Oncol 1990, 8, 736-740.
8. Johnson PWM, Burchill SA, Selby PJ. The molecular detection of circulating tumour cells. Br J Cancer 1995, 72, 268-276.
9. Kwon BS. Pigmentation genes: the tyrosinase gene family and the pmel 17 gene family. J Invest Dermatol 1993, 100(2 Suppl.), 134S-140S.
10. Chen YT, Stockert E, Tsang S, Coplan KA, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc NatlAcad Sci USA 1994, 92, 8125-8129.
11. Kwon BS, Haq AK, Pomerantz SH, Halaban R. Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci USA 1987, 84, 7473-7477.
12. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991,338, 1227-1229.
13. Adema GJ, de Boer AJ, Vogel AM, Leonen WA, Figdor CG. Molecular characterization of the melanoma lineage specific antigen gplOO. J Biol Chem 1994, 269, 20126-20133.
14. Coulie PG, Brichard V, van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic lymphocytes on HLA-A2 melanomas. J Exp Med 1994, 180, 35-42.
15. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994, 91, 3515-3519.
16. Carrel S, Dore JF, Ruiter D, et al. The EORTC melanoma group exchange program: evaluation of a multicenter monoclonal antibody study. Int J Cancer 1991, 48, 836-847.
17. Scheibenbogen C, Weyers I, Ruiter D, Lee K-H, Bittinger A, Keilholz U. Expression of the melanoma antigen gp100 in metastases resected prior to and following treatment with IFNα and IL-2. J Immunotherapy 1996, 19, 375-380.
18. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in situ lesions. J Immunotherapy 1996, 19, 192-205.
19. Keilholz U (for the EORTC Melanoma Cooperative Group). Diagnostic PCR in melanoma, methods and quality assurance. Epalinges, Switzerland, 26/27 January 1996. Eur J Cancer 1996, 32, 1661-1663.
20. Chen YT, Stockert E, Jungbluth A, et al. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996, 93, 5915-5919.
21. Brasseur F, Rimoldi D, Lienard D, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995, 63, 375-380.
22. Hoon DSB, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995, 13, 2109-2116.
23. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162, 156.
24. Brichard VG, Herman J, van Pel A, et al. A tyrosinase nonapeptide presented by HLA B44 is recognized on a human melanoma by autologous cytolytic lymphocytes. Eur J Immunol 1996, 26, 224-230.
25. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Möhler T, Hunstein W. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993, 101, 887-890.
26. Battayani Z, Grob J, Xerri L, et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995, 131, 443-447.
27. Mellado B, Colomer D, Castel T, et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with stage and prognosis. J Clin Oncol 1996, 14, 2091-2097.
28. Foss AJ, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995, 72, 155-159.
29. Reinhold U, Lüdtke-Handjery HC, Schnautz S, Kreysel HW, Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997, 108, 166-169.
30. Kunter U, Buer J, Probst M, et al. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 1996, 88, 590-594.
31. Pittman K, Burchill SA, Smith B, et al. Reverse-transcriptase polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 1996, 7, 297-301.
32. Brossart P, Keilholz U, Scheibenbogen C, Möhler T, Willhauck M, Hunstein W. Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J Immunotherapy 1994, 15, 38-41.
33. Curry BJ, Smith MJ, Hersey P. Detection and quantitation of melanoma cells in the circulation of patients. Melanoma Res 1996, 6, 45-54.
34. Brossart P, Schmier J, Krüger S, et al. A PCR-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1995, 55, 4065-4068.
35. Zaaijer HL, Cuypers HTM, Reesink HW, Winkel IN, Gerken G, Lelie PN. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993, 341, 722-724.
36. Buzaid AC, Balch CM. Polymerase chain reaction of melanoma in peripheral blood: too early to assess clinical value. J Natl Cancer Inst 1996, 88, 569-570.
37. Jung FA, Buzaid AC, Ross MI, et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 1997, 15, 2826-2831.